Oral Corticosteroid (OCS)

DRUG2 trials

Sponsors

Teva Branded Pharmaceutical Products R&D, Inc., McMaster University

Conditions

AsthmaElevated Blood EosinophilsOral Corticosteroid Dependence

Phase 3

An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils

CompletedNCT02501629

Teva Branded Pharmaceutical Products R&D, Inc.Asthma, Elevated Blood Eosinophils, Oral Corticosteroid Dependence

Start: 2015-09-29End: 2017-12-04Updated: 2021-11-09

Phase 4

Therapeutic Relevance of Abnormal Airway Morphology in Asthma

RecruitingNCT06970080

McMaster UniversityAsthma

Start: 2025-06-02End: 2028-06-30Target: 242Updated: 2025-09-11

Related Papers

Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.

2020-02-1462 citations